Showing 20 of 24 recruiting trials for “primary-peritoneal-carcinoma”
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
👨⚕️ Gabriel A. Brooks, MD, MPH, Alliance for Clinical Trials in Oncology📍 271 sites📅 Started Feb 2026View details ↗
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
PTC-Guided Therapy for Peritoneal Mesothelioma
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
👨⚕️ Siddharth Sheth, Alliance for Clinical Trials in Oncology📍 175 sites📅 Started Mar 2025View details ↗
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
👨⚕️ Nicole C Schmitt, MD, FACS, Emory University Hospital/Winship Cancer Institute📍 1 site📅 Started Mar 2025View details ↗
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
👨⚕️ Nicole C Schmitt, D, FACS, Emory University Hospital/Winship Cancer Institute📍 2 sites📅 Started Dec 2024View details ↗
[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
👨⚕️ Yongkun Sun, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical SciencesCancer📍 1 site📅 Started Jan 2024View details ↗
RecruitingNCT06581549 ↗
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
👨⚕️ Giulia Pasello, MD, Istituto Oncologico Veneto IOV IRCCS📍 10 sites📅 Started Nov 2023View details ↗
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
👨⚕️ Malcolm D Mattes, University Health Network Princess Margaret Cancer Center LAO📍 18 sites📅 Started Sep 2022View details ↗
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
👨⚕️ Robert W. Holloway, MD, AdventHealth Cancer Institute📍 31 sites📅 Started Aug 2022View details ↗
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
👨⚕️ Dukagjin M Blakaj, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started May 2022View details ↗
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →